会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • NOVEL GH-RH ANALOGS WITH POTENT AGONISTIC EFFECTS
    • 新的GH-RH模拟与POTENT激发效应
    • WO2013095903A1
    • 2013-06-27
    • PCT/US2012/067690
    • 2012-12-04
    • SCHALLY, Andrew, V.CAI, Ren-ZhiZARANDI, MartaUNIVERSITY OF MIAMIUNITED STATES OF AMERICA REPRESENTED BY THE DEPARMENT OF VETERANS AFFAIRS
    • SCHALLY, Andrew, V.CAI, Ren-ZhiZARANDI, Marta
    • C07K14/60A61K38/25
    • C07K14/60A61K38/00C07K14/61
    • The synthetic peptides have the sequence: [RrA\ A 2 , A 6 , A 8, A 11 , A 12 , A 15 , A 20 , A 21 , A 22 , Nle 27 , A 28 , A 29 , A30]hGH-RH(1 -30)-R 2 (SEQ ID NO: 1 ) wherein R 1 is Ac, Tfa, or is absent, A 1 is Tyr, Dat, or N-Me-Tyr, A 2 is Ala, D-Ala, Abu, or D-Abu, A 6 is Phe or Fpa5, A 8 is Asn, Ala, Gin, Thr, or N-Me-Ala, A 11 is Arg, His, or Har, A 12 is Orn, or Lys(Me)2, A 15 is Abu or Ala A 20 is Arg, His, or Har, A 21 is Orn, or Lys(Me)2, A 22 is Leu, or Orn, A 28 is Ser, or Asp, A 29 is Arg, Har, Agm, D-Arg, or D-Har, A 30 is Arg, Agm, Ada, Amc, Aha, Apa, Har, D-Arg, D-Har, Gab, Gin, D-GIn, Gin-Gab, D-Gln-Gab, or is absent, R 2 is -NH 2 , -OH, -NHR 2 , -N(R 2 ) 2 , or -OR 2 , in which R 2 is any of C 1-12 alkyl, C 2-12 alkenyl, or C 2-12 alkinyl, provided that if A 29 is Agm then A 30 and R 2 are absent A 1 is N-Me-Tyr only, and pharmaceutically acceptable salts thereof.
    • 合成肽具有以下序列:[RrA / A2,A6,A8,A11,A12,A15,A20,A21,A22,Nle27,A28,A29,A30] hGH-RH(1-30)-R2(SEQ ID NO :1)其中R1是Ac,Tfa或不存在,A1是Tyr,Dat或N-Me-Tyr,A2是Ala,D-Ala,Abu或D-Abu,A6是Phe或Fpa5,A8是 Asn,Ala,Gin,Thr或N-Me-Ala,A11是Arg,His或Har,A12是Orn或Lys(Me)2,A15是Abu或Ala A20是Arg,His或Har,A21 是Orn或Lys(Me)2,A22是Leu或Orn,A28是Ser或Asp,A29是Arg,Har,Agm,D-Arg或D-Har,A30是Arg,Agm,Ada,Amc ,Aha,Apa,Har,D-Arg,D-Har,Gab,Gin,D-Gln,Gin-Gab,D-Gln-Gab,或不存在,R 2是-NH 2,-OH,-NHR 2,-N (R2)2或-OR2,其中R2是C1-12烷基,C2-12烯基或C2-12炔基中的任何一个,条件是如果A29是Agm,则A30和R2不存在A1是N-Me-Tyr 仅及其药学上可接受的盐。
    • 4. 发明申请
    • POLYPEPTIDE BOMBESIN ANTAGONISTS
    • 多肽BOMBESIN拮抗剂
    • WO1994021674A1
    • 1994-09-29
    • PCT/US1994002511
    • 1994-03-07
    • THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDSCHALLY, Andrew, V.CAI, Ren, Zhi
    • THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    • C07K07/08
    • C07K7/086A61K38/00
    • Pseudopeptides comprising a peptide of formula (I): X-A -A -Trp-Ala-Val-Gly-His-Leu-p &cir& _s &cir& _i &cir& _-A -Q wherein X is hydrogen, a single bond linking the alpha amino group of A to the gamma carboxyl moiety on the 3-priopionyl moiety of A when A is Glu, or a group of formula R CO- wherein R is selected from the groups consisting of: a) hydrogen, C1-10alkyl, phenyl or phenyl-C1-10-alkyl, p-Hl-phenyl, p-Hl-phenyl-C1-10-alkyl, naphthyl, naphthyl-C1-10-alkyl, indolyl, indolyl-C1-10-alkyl, pyridyl, pyridyl-C1-10-alkyl, thienyl, thienyl-C1-10-alkyl, cyclohexyl or cyclohexyl-C1-10-alkyl, where Hl = F, Cl, Br, OH, CH3 or OCH3; b) N(R )(R )-, wherein R is hydrogen, C1-10alkyl, phenyl or phenyl-C1-10-alkyl, R is hydrogen or C1-10alkyl; c) R O-, wherein R is C1-10alkyl, phenyl or phenyl-C1-10-alkyl; A is a D- or L-amino acid residue selected from the group consisting of Phe, p-Hl-Phe, pGlu, Nal, Pal, Tpi, unsubstituted Trp or Trp substituted in the benzene ring by one or more members selected from the group consisting of F, Cl, Br, NH2 or C1-3alkyl; or A is a peptide bond linking the acyl moiety of R CO- to the alpha amino moiety of A ; A is Gln, Glu[-], Glu(Y) or His, wherein [-] is a single bond linking the gamma carboxyl group of A when A is Glu with the alpha amino group of A where X is a single bond, Y is -OR or -N(R )(R ) wherein R is hydrogen, C1-3alkyl or phenyl; R is hydrogen or C1-3alkyl; and R is hydrogen, C1-3alkyl or -NHCONH2; Leu-p &cir& _s &cir& _i &cir& _- is a reduced form of Leu wherein the C = O moiety of Leu is instead -CH2- such that the bond of this -CH2- moiety with the alpha amino moiety of the adjacent A residue is a pseudopeptide bond; A is Tac, MTac, or DMTac; and Q is NH2 or OQ where Q is hydrogen, C1-10alkyl, phenyl or phenyl-C1-10-alkyl; and the pharmaceutically acceptable acids or salts thereof.
    • 包含式(I)的肽的假肽:XA 1 -A 2 -Trp-Ala-Val-Gly-His-Leu-p&cir&amp; s&cir&amp; A-A 9 -Q其中X是氢 当A 2为Glu时,将A 1的α氨基与A 2的3-取代基部分上的γ羧基部分连接的单键,或式R 1 CO-的基团,其中 R 1选自:a)氢,C 1-10烷基,苯基或苯基-C 1-10 - 烷基,对-1-苯基,对-1-苯基-C1-10-烷基,萘基, 萘基-C 1-10烷基,吲哚基,吲哚基C 1-10 - 烷基,吡啶基,吡啶基-C 1-10烷基,噻吩基,噻吩基-C1-10-烷基,环己基或环己基-C1-10-烷基,其中H1 = F,Cl,Br,OH,CH 3或OCH 3; b)N(R 2)(R 3) - ,其中R 2是氢,C 1-10烷基,苯基或苯基-C 1-10烷基,R 3是氢或C 1-10烷基; c)R 4 O-,其中R 4是C 1-10烷基,苯基或苯基-C 1-10 - 烷基; A 1是选自由Phe,p-H1-Phe,pGlu,Nal,Pal,Tpi组成的组的D-或L-氨基酸残基,在苯环中被一个或多个成员取代的未取代的Trp或Trp 选自F,Cl,Br,NH 2或C 1-3烷基; 或A 1是将R 1 CO-的酰基部分与A 2的α氨基部分连接的肽键; A 2是Gln,Glu [ - ],Glu(Y)或His,其中[ - ]是当A 2是Glu时与A 2的γ羧基连接的单键, A 1其中X是单键,Y是-OR 5或-N(R 5)(R 6),其中R 5是氢,C 1-3烷基或苯基; R 6是氢或C 1-3烷基; 和R 7是氢,C 1-3烷基或-NHCONH 2; Leu-p&cir&_ s&cir&_i&cir _ _是Leu的还原形式,其中Leu的C = O部分代替-CH2-,使得该-CH 2 - 部分与相邻A <9的α氨基部分的键 >残基是假肽键; A <9>是Tac,MTac或DMTac; Q是NH 2或OQ 1,其中Q 1是氢,C 1-10烷基,苯基或苯基-C 1-10 - 烷基; 和其药学上可接受的酸或其盐。
    • 6. 发明申请
    • NONAPEPTIDE BOMBESIN ANTAGONISTS
    • 非特异性BOMBESIN ANTAGONISTS
    • WO1992009626A1
    • 1992-06-11
    • PCT/US1991008534
    • 1991-11-15
    • THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDSCHALLY, Andrew, V.CAI, Ren, Zhi
    • THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    • C07K07/02
    • C07K7/086A61K38/00Y02P20/55
    • The novel pseudo polypeptides of this invention are potent bombesin antagonists. There are provided processes for their production, pharmaceutical compositions comprising said polypeptides and their use as pharmaceutically active agents. More particularly the present invention provides pseudopeptides comprising a nonapeptide moiety of formula (I): X-A?1-A2-A3-A4-A5-A6-A7-A8¿-psi-A9-Q, wherein Q is NH¿2? or OQ?1¿ where Q1 is hydrogen, C¿1-10?alkyl, phenyl or phenyl-C7-10-alkyl; X is hydrogen or a single bond linking to A?2¿, the acyl residue of an organic acid, or a group of formula R1CO- wherein 1) R1 is hydrogen, C¿1-10?alkyl, phenyl or phenyl-C7-10-alkyl; 2) R?1¿CO- is a) R2.N(R3)-CO- wherein R2 is hydrogen, C¿1-10?alkyl, phenyl or C7-10phenyl-C7-10-alkyl, R?3¿ is hydrogen or C¿1-10? alkyl; b) R?4¿-O-CO- wherein R4 is C¿1-10?alkyl, phenyl or phenyl-C7-10-alkyl. A?1¿ is D-, L- or DL-pGlu, Nal, Phe, Thi, Tyr, Tpi, Hca, Hpp, Mpp, Trp or Trp substituted in the benzene ring by one or more members selected from the group consisting of halogen, NO¿2?, NH2, OH, C1-3 alkyl and C1-3 alkoxy wherein halogen is fluorine, chlorine and bromine, A?2¿ is Asn, Dpa, Gln, His, MeHis, His(Bz), His(Z) or a group of formula Dpa (X), Asp (Y), Glu [-] and Glu (Y); wherein X is as above, Y is -OR?5 or R6-NR7¿ wherein R5 is hydrogen, C¿1-3?alkyl or phenyl; R?6¿ is hydrogen or C¿1-3?alkyl; R?7¿ is hydrogen, C¿1-3?alkyl or -NHCONH2 and [-] is a single bond linking the side carboxyl group with the alpha amino group of A?1¿ where X is a single bond, A3 is Nal, Pal, Tpi, Trp, MeTrp, Trp(For) or Trp substituted in the benzene ring by one or more members selected from the group consisting of halogen, NO¿2?, NH2, OH, C1-3 alkyl and C1-3 alkoxy wherein halogen is fluorine, chlorine and bromine; A?4¿ is Ala, MeAla or Gln; A5 is Val or MeVal; A6 is Gly, Phe or D-Ala; A7 is His, MeHis, His(Bz), His(Z), Lys(Z) or Pal; A8 is a reduced isostere of Leu or Phe; A9 is Leu, Phe, Tpi, Trp or Trp substituted in the benzene ring by one or more members selected from the group consisting of halogen, NO¿2?, NH2, OH, C1-3alkyl and C1-3alkoxy wherein halogen is fluorine, chlorine and bromine; provided that where A?9¿ is Leu or Phe, A1 is other than D-Nal or DL-Phe and where A1 is D-Nal or DL-Phe, A9 is other than Leu or Phe and the salts thereof with pharmaceutically acceptable acids.